Top of this page
Skip navigation, go straight to the content Newsroom UCB U.S. News


UCB Statement on COVID-19 Outbreak

  • UCB_LOGO_1280x960Patients are at the heart of everything we do, and UCB is committed to helping those impacted by the novel coronavirus, COVID-19. This includes helping patients maintain access to and answering any questions about UCB medicines, as well as putting patient and community care first in all our actions during these uncertain times.

    The evolving COVID-19 pandemic has placed tremendous strain on medical healthcare systems worldwide as they focus on the ongoing extraordinary medical emergency. Taking this into consideration, UCB has taken measures to protect the patients we serve and others around the world.

    We are committed to assuring reliable supply of medicines in every market where we have a commercial presence. Despite the rapid emergence of the novel coronavirus and the challenge presented to healthcare systems around the globe, UCB has not experienced shortages for any of our products due to this epidemic.

    Since the onset of the coronavirus outbreak, UCB has been closely monitoring our supply chain for potential impact to the supply of our medicines around the world. UCB leverages strategic buffer stock along with multi-sourcing for key materials in our global supply chain to mitigate the impact of supply disruptions due to events such as the current coronavirus outbreak.

    Our global manufacturing and distribution network continues to be fully operational and UCB remains in constant contact with our global network of key suppliers, manufacturing partners, and distributors to identify potential risks and take appropriate measures to avoid any disruption. At this time, we do not anticipate any supply disruption of our products. As this global situation evolves, we will continue to take the steps necessary to safeguard the reliable supply of our medicines.

    Clinical Trials
    In the context of pressurised health systems and with our primary focus on the safety of our patients, UCB has decided to take the following precautionary approach with regards to our clinical studies:

    • To not initiate any new studies.
    • To temporarily halt recruitment into our ongoing clinical studies.  Any exceptions to this are communicated by the program teams to the respective investigators.
    • For all patients who have been recruited into any UCB study, we will continue to focus on the care, access to study medication, clinical evaluations and safety monitoring. Taking a pragmatic approach, UCB is reviewing site visit requirements for regions and sites most impacted by the pandemic.  Any adaptations made will be proactively communicated to participants.

    We believe these measures will help lessen the impact on the local health care provision, reduce the risk of patients being unable to receive full and appropriate medical oversight and avoid the inherent risk of study driven hospital/site visits. We will continue to monitor the situation and update guidance to investigators as needed.

    Additional Info
    We have suspended all proactive face-to-face activity between our field-based personnel and Health Care Providers. We have asked that our employees remain responsive to any needs that may arise in the local areas and provide support for patients and stakeholders, if requested and feasible.

    In addition, ucbCARES stands ready to help anyone impacted by COVID-19 find answers to their questions and ensuring they receive the respect and care they deserve during this concerning time. Contact ucbCARES at +1-844-599-CARE (2273), via email at, or visit:

    As we navigate this unpredictable situation together as a global community, UCB’s commitment to supporting patients living with severe, chronic diseases remains unchanged. From our team at UCB, our hearts go out to all those affected by COVID-19, and we are here to help.

  • Like